Open AccessThis article is
- freely available
Antisense Gene Silencing: Therapy for Neurodegenerative Disorders?
Danish Dementia Research Centre, Neurogenetics Clinic, Department of Neurology, Section 6702, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, DK-2100, Copenhagen Ø, Denmark
Department of Cellular and Molecular Medicine, Section of Neurogenetics, The Panum Institute, University of Copenhagen, Blegdamsvej 3, DK-2200 Copenhagen N, Denmark
* Author to whom correspondence should be addressed.
Received: 20 May 2013; in revised form: 11 July 2013 / Accepted: 13 August 2013 / Published: 10 September 2013
Abstract: Since the first reports that double-stranded RNAs can efficiently silence gene expression in C. elegans, the technology of RNA interference (RNAi) has been intensively exploited as an experimental tool to study gene function. With the subsequent discovery that RNAi could also be applied to mammalian cells, the technology of RNAi expanded from being a valuable experimental tool to being an applicable method for gene-specific therapeutic regulation, and much effort has been put into further refinement of the technique. This review will focus on how RNAi has developed over the years and how the technique is exploited in a pre-clinical and clinical perspective in relation to neurodegenerative disorders.
Keywords: RNA interference; neurodegenerative disorders; CNS
Citations to this Article
Cite This Article
MDPI and ACS Style
Nielsen, T.T.; Nielsen, J.E. Antisense Gene Silencing: Therapy for Neurodegenerative Disorders? Genes 2013, 4, 457-484.
Nielsen TT, Nielsen JE. Antisense Gene Silencing: Therapy for Neurodegenerative Disorders? Genes. 2013; 4(3):457-484.
Nielsen, Troels T.; Nielsen, Jørgen E. 2013. "Antisense Gene Silencing: Therapy for Neurodegenerative Disorders?" Genes 4, no. 3: 457-484.